Resources

Clinical Trials

Marburg and Sudan Ebolavirus

Phase 1b Marburg and Sudan vaccine trial (Uganda)

Phase 1b Marburg and Sudan vaccine trial (U.S.)

Marburg Vaccine Trials

Phase 1 Marburg virus vaccine trial (U.S.) | Results

Phase 2 Marburg virus vaccine trial (Uganda and Kenya) (clinicaltrials.gov)

Phase 2 Marburg virus vaccine trial (Uganda and Kenya) (Pan African trials registry)

Phase 2 Marburg virus vaccine trial (Rwanda) (Pan African trials registry)

Phase 2 Marburg virus vaccine trial (U.S.)

Sudan Ebola Vaccine Trials

Phase 1 Sudan ebolavirus vaccine trial (Uganda) | Results

Phase 2 Sudan ebolavirus vaccine trial (Uganda and Kenya) (clinicaltrials.gov)

Phase 2 Sudan ebolavirus vaccine trial (Uganda and Kenya) (Pan African trials registry)

Factsheets

Marburg virus factsheet

Sudan ebolavirus factsheet

Findings, Studies, and Publications

National Institutes of Health: Marburg vaccine shows promising results in first-in-human study

Lancet Infectious Diseases, 2023: Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial

Sabin-Aspen Vaccine Science & Policy Group: Powering Vaccine R&D: Opportunities for Transformation

BARDA: BARDA continues partnership with Sabin for two filovirus vaccines

Sabin R&D News: For the latest on our vaccine development